202 related articles for article (PubMed ID: 34427023)
1. Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
Lin J; Elkon J; Ricart B; Palmer E; Zevallos-Delgado C; Noonepalle S; Burgess B; Siegel R; Ma Y; Villagra A
Oncologist; 2021 Dec; 26(12):e2136-e2142. PubMed ID: 34427023
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
[TBL] [Abstract][Full Text] [Related]
3. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
4. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.
Tripathi A; Supko JG; Gray KP; Melnick ZJ; Regan MM; Taplin ME; Choudhury AD; Pomerantz MM; Bellmunt J; Yu C; Sun Z; Srinivas S; Kantoff PW; Sweeney CJ; Harshman LC
Clin Cancer Res; 2020 Dec; 26(23):6122-6131. PubMed ID: 32943461
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Caffo O; Ortega C; Nolè F; Gasparro D; Mucciarini C; Aieta M; Zagonel V; Iacovelli R; De Giorgi U; Facchini G; Veccia A; Palesandro E; Verri E; Buti S; Razzini G; Bozza G; Maruzzo M; Ciccarese C; Schepisi G; Rossetti S; Maines F; Kinspergher S; Fratino L; Ermacora P; Nicodemo M; Giordano M; Sartori D; Scapoli D; Sabbatini R; Lo Re G; Morelli F; D'Angelo A; Vittimberga I; Lippe P; Carrozza F; Messina C; Galli L; Valcamonico F; Porta C; Pappagallo G; Aglietta M
Eur J Cancer; 2021 Sep; 155():56-63. PubMed ID: 34358777
[TBL] [Abstract][Full Text] [Related]
7. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Abida W; Hahn AW; Shore N; Agarwal N; Sieber P; Smith MR; Dorff T; Monk P; Rettig M; Patel R; Page A; Duff M; Xu R; Wang J; Barkund S; Pankov A; Wang A; Junttila MR; Multani PS; Daemen A; Chow Maneval E; Logothetis CJ; Morris MJ
Clin Cancer Res; 2024 Mar; 30(6):1111-1120. PubMed ID: 38226958
[TBL] [Abstract][Full Text] [Related]
9. Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.
Shore ND; Schellhammer PF; Tutrone RF; Mariados NF; Harrelson SS
Clin Genitourin Cancer; 2020 Oct; 18(5):416-422. PubMed ID: 32475774
[TBL] [Abstract][Full Text] [Related]
10. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer.
Vinh-Hung V; Natchagande G; Joachim C; Gorobets O; Drame M; Bougas S; Folefac E; Nguyen NP; Verschraegen C; Yin M
Clin Genitourin Cancer; 2020 Dec; 18(6):e660-e668. PubMed ID: 32414694
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results.
Maughan BL; Kessel A; McFarland TR; Sayegh N; Nussenzveig R; Hahn AW; Hoffman JM; Morton K; Sirohi D; Kohli M; Swami U; Boucher K; Haaland B; Agarwal N
Oncologist; 2021 Dec; 26(12):1006-e2129. PubMed ID: 34423501
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Madan RA; Karzai F; Donahue RN; Al-Harthy M; Bilusic M; Rosner II; Singh H; Arlen PM; Theoret MR; Marté JL; Cordes L; Couvillon A; Hankin A; Williams M; Owens H; Lochrin SE; Chau CH; Steinberg S; Figg WD; Dahut W; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33664086
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Sarker D; Dawson NA; Aparicio AM; Dorff TB; Pantuck AJ; Vaishampayan UN; Henson L; Vasist L; Roy-Ghanta S; Gorczyca M; York W; Ganji G; Tolson J; de Bono JS
Clin Cancer Res; 2021 Oct; 27(19):5248-5257. PubMed ID: 34281912
[TBL] [Abstract][Full Text] [Related]
19. Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
Tsuzuki S; Nakanishi S; Tamaki M; Oshiro T; Miki J; Yamada H; Shimomura T; Kimura T; Furuta N; Saito S; Egawa S
PLoS One; 2021; 16(10):e0258160. PubMed ID: 34597353
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
